摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-苯磺酰氨基苯甲酸甲酯 | 107922-46-3

中文名称
3-苯磺酰氨基苯甲酸甲酯
中文别名
——
英文名称
methyl 3-(phenylsulfonamido)benzoate
英文别名
3-Benzolsulfonylamino-benzoesaeuremethylester;Methyl 3-(Phenylsulfonyl)aminobenzoate;Methyl 3-benzenesulfonamidobenzoate;methyl 3-(benzenesulfonamido)benzoate
3-苯磺酰氨基苯甲酸甲酯化学式
CAS
107922-46-3
化学式
C14H13NO4S
mdl
——
分子量
291.328
InChiKey
SPIPPTXOJKWUKC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    448.1±47.0 °C(Predicted)
  • 密度:
    1.345±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    80.8
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2935009090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温下,应保持干燥密封。

SDS

SDS:d9aa854968d99cd1af540bca2a1c1f6a
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 3-benzenesulfonamidobenzoate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-benzenesulfonamidobenzoate
CAS number: 107922-46-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H13NO4S
Molecular weight: 291.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup
    摘要:
    A potent series of inhibitors against the B-RafV600E kinase have been developed that show excellent activity in cellular assays and good oral bioavailability in rats. The key structural features of the series are an arylsulfonamide headgroup, a thiazole core, and a fluorine ortho to the sulfonamide nitrogen. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.06.021
  • 作为产物:
    描述:
    间氨基苯甲酸吡啶硫酸 作用下, 以 二氯甲烷 为溶剂, 生成 3-苯磺酰氨基苯甲酸甲酯
    参考文献:
    名称:
    Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup
    摘要:
    A potent series of inhibitors against the B-RafV600E kinase have been developed that show excellent activity in cellular assays and good oral bioavailability in rats. The key structural features of the series are an arylsulfonamide headgroup, a thiazole core, and a fluorine ortho to the sulfonamide nitrogen. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.06.021
点击查看最新优质反应信息

文献信息

  • [EN] BENZIMIDAZOLECARBOXAMIDES AS INHIBITORS OF FAK<br/>[FR] BENZIMIDAZOLECARBOXAMIDES CONSTITUANT DES INHIBITEURS DE LA KINASE D'ADHÉRENCE FOCALE
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2010126922A1
    公开(公告)日:2010-11-04
    This invention relates to benzimadolecarboxamides of formula (I) which are inhibitors of focal adhesion kinase, and as such are useful for treating proliferative diseases.
    这项发明涉及式(I)的苯并咪唑羧酰胺,它们是黏附斑激酶的抑制剂,因此可用于治疗增殖性疾病。
  • Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa
    申请人:3-Dimensional Pharmaceuticals, Inc.
    公开号:US05741819A1
    公开(公告)日:1998-04-21
    The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: ##STR1## or pharmaceutically acceptable salts thereof; wherein R.sup.1 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; R.sup.2 is one of hydrogen, alkyl, cycloalkyl or aryl; R.sup.3 is one of hydrogen, hydroxy or alkoxy; R.sup.4 is one of --NH.sub.2, phenyl or pyridyl, wherein said phenyl and said pyridyl are optionally substituted with one or two of halogen, hydroxy, hydroxyalkyl, alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl and/or dialkylaminoalkyl; X is one of --CH.sub.2 -- or --C(O)--; and n is from zero to eleven; provided that when R.sup.4 is --NH.sub.2, then R.sup.3 is hydrogen and n is other than zero; and also provided that when R.sup.3 is hydroxy or alkoxy, then R.sup.4 is other than --NH.sub.2, and n is other than zero.
    本发明涉及用于治疗动脉和静脉血栓性闭塞性疾病、炎症、癌症和神经退行性疾病的非肽因子Xa抑制剂。因子Xa抑制剂提供结构化合物:##STR1##或其药学上可接受的盐;其中R.sup.1是烷基、取代烷基、环烷基、芳基、取代芳基、杂环芳基或取代杂环芳基;R.sup.2是氢、烷基、环烷基或芳基中的一种;R.sup.3是氢、羟基或烷氧基中的一种;R.sup.4是--NH.sub.2、苯基或吡啶基中的一种,其中所述苯基和所述吡啶基可以选择地取代为卤素、羟基、羟基烷基、烷氧基、基、单烷基基、二烷基基、基烷基、单烷基基烷基和/或二烷基基烷基中的一种或两种;X是--CH.sub.2--或--C(O)--中的一种;n为零到十一;但是当R.sup.4为--NH.sub.2时,R.sup.3为氢且n不为零;同时当R.sup.3为羟基或烷氧基时,R.sup.4不为--NH.sub.2,且n不为零。
  • Sequential C–S and S–N Coupling Approach to Sulfonamides
    作者:Kai Chen、Wei Chen、Bing Han、Wanzhi Chen、Miaochang Liu、Huayue Wu
    DOI:10.1021/acs.orglett.0c00183
    日期:2020.3.6
    A one-pot three-component reaction involving nitroarenes, (hetero)arylboronic acids, and potassium pyrosulfite leading to sulfonamides was described. A broad range of sulfonamides bearing different reactive functional groups were obtained in good to excellent yields through sequential C-S and S-N coupling that does not require metal catalysts.
    描述了涉及硝基芳烃,(杂)芳基硼酸和焦亚硫酸的一锅三组分反应,生成磺酰胺。通过不需要属催化剂的连续CS和SN偶联,获得了具有不同反应性官能团的多种磺酰胺,收率好至极好。
  • Design and Synthesis of Small Molecule Glycerol 3-Phosphate Acyltransferase Inhibitors
    作者:Edward A. Wydysh、Susan M. Medghalchi、Aravinda Vadlamudi、Craig A. Townsend
    DOI:10.1021/jm900251a
    日期:2009.5.28
    mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the rate-limiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series
    肥胖症和其他与甘油三酯含量增加相关的疾病的发病率正在迅速增长,尤其是在美国。甘油 3-磷酸酰基转移酶 (GPAT) 催化甘油生物合成的限速步骤,即甘油 3-磷酸与饱和长链酰基辅酶 A 的酰化。为了生产这种酶的小分子抑制剂,设计并合成了一系列苯甲酸膦酸。该系列的体外测试导致鉴定了几种化合物,特别是 2-(壬基磺酰胺基)苯甲酸 ( 15g ),在完整线粒体分析中具有中等 GPAT 抑制活性。
  • Copper-catalyzed cross-coupling of sulfonamides with aryl iodides and bromides facilitated by amino acid ligands
    作者:Wei Deng、Lei Liu、Chen Zhang、Min Liu、Qing-Xiang Guo
    DOI:10.1016/j.tetlet.2005.08.149
    日期:2005.10
    A highly general, convenient, and inexpensive catalyst system was developed for the N-arylation of sulfonamides with aryl iodides or bromides by using 5–20 mol % of CuI as catalyst, 20 mol % of N-methylglycine (for aryl iodides) or N,N-dimethylglycine (for aryl bromides) as ligand, and K3PO4 as base.
    高度通常,方便,廉价的催化剂体系用于将显影Ñ通过使用5-20%(摩尔)的CuI作为催化剂的,20摩尔%的与芳基化物或化物磺胺-arylation Ñ -methylglycine(为芳基化物)或ñ,N-二甲基甘酸(对于芳基化物)为配体,K 3 PO 4为碱。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫